Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France.
Valentine GrumbergChristos ChouaidFrancois-Emery CottéBaptiste JouanetonRonan JolivelAnne-Françoise GaudinDorothée ReynaudJean-Baptiste AssiéIsabelle BorgetPublished in: Journal of medical economics (2022)
HCRU and costs for NSCLC patients treated with nivolumab decreased over time. Cost estimates are dependent on the statistical method used to take into account uncertainty, but costs decreased over time whatever the method used.
Keyphrases
- advanced non small cell lung cancer
- healthcare
- epidermal growth factor receptor
- end stage renal disease
- small cell lung cancer
- newly diagnosed
- chronic kidney disease
- palliative care
- prognostic factors
- emergency department
- quality improvement
- patient reported outcomes
- chronic pain
- patient reported
- tyrosine kinase
- pain management
- brain metastases